HC Wainwright Predicts Nkarta's Q3 Earnings (NASDAQ:NKTX)

Key Points

• HC Wainwright forecast Nkarta will lose $0.46 per share in Q3 2026 and reiterated a Buy rating. Its estimates include losses of $1.86 per share for FY2026 and $2.26 for FY2027.
• Analyst opinions are mixed, but Nkarta has a MarketBeat average rating of “Moderate Buy” and an average price target of $11.20; one analyst rates it Strong Buy, five Buy, and one Sell.
• Nkarta reported a quarterly loss of $0.54 per share in its latest results, missing the consensus estimate of a $0.36 loss. The stock opened at $1.53, near its one-year low of $1.48.

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Nkarta in a research note issued on Monday, November 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.46) per share for the quarter. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Nkarta's Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.57) EPS and FY2030 earnings at ($1.36) EPS.

Several other research analysts also recently commented on NKTX. Wall Street Zen downgraded Nkarta from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Stifel Nicolaus lowered their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nkarta in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nkarta has an average rating of "Moderate Buy" and an average target price of $11.20.

Nkarta Price Performance

Shares of NASDAQ NKTX opened at $1.53 on Wednesday. The company has a 50 day simple moving average of $2.40 and a 200 day simple moving average of $2.52. The firm has a market cap of $109.58 million, a PE ratio of -0.97 and a beta of 1.24. Nkarta has a 1 year low of $1.48 and a 1 year high of $3.72.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.18).

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NKTX. BlackRock Inc. acquired a new stake in shares of Nkarta during the 2nd quarter worth approximately $17,830,000. Monaco Asset Management SAM bought a new stake in shares of Nkarta in the 2nd quarter valued at $6,717,000. Renaissance Technologies LLC lifted its position in shares of Nkarta by 1.8% during the 1st quarter. Renaissance Technologies LLC now owns 1,732,372 shares of the company's stock valued at $3,655,000 after acquiring an additional 30,350 shares during the period. AWM Investment Company Inc. acquired a new position in shares of Nkarta during the 2nd quarter valued at $2,564,000. Finally, Dimensional Fund Advisors LP boosted its stake in Nkarta by 74.4% during the first quarter. Dimensional Fund Advisors LP now owns 346,593 shares of the company's stock worth $731,000 after acquiring an additional 147,894 shares in the last quarter. 80.54% of the stock is owned by institutional investors.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta's research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.